UBS Maintains Neutral on RXO, Lowers Price Target to $23

Benzinga Newsdesk www.benzinga.com Negative 82.8%

Neg 82.8% Neu 0% Pos 0%

UBS analyst Thomas Wadewitz maintains RXO (NYSE:RXO) with a Neutral and lowers the price target from $26 to $23.

Comments

No comments yet. Be the first!